Abstract:Pathogenic variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified that increase the risk for developing Parkinson's disease in a dominantly inherited fashion. These pathogenic variants, of which G2019S is the most common, cause abnormally high kinase activity, and compounds that inhibit this activity are being pursued as potentially disease-modifying therapeutics. Because LRRK2 regulates important cellular processes, developing inhibitors that can selectively target the pathogenic variant while sparing normal LRRK2 activity could offer potential advantages in heterozygous carriers. We conducted a high-throughput screen and identified a single selective compound that preferentially inhibited G2019S-LRRK2. Optimization of this scaffold led to a series of novel, potent, and highly selective G2019S-LRRK2 inhibitors.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01243?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01243</a>.Compound 1 homology model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_001.pdb">PDB</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_002.csv">CSV</a>)Kinase panel for compound 31 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_003.csv">CSV</a>)Crystal data for compound (R)-32; 1H NMR and HPLC traces for compounds 1, 4, 7, 19, 20, 21, 22, 23, 25, 26, 30, and 31; and table of geometric mean and geometric standard deviation of biochemical potency (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_004.pdf">PDF</a>)This article has not yet been cited by other publications.

GSK 2578215 A ; A Potent and Highly Selective 2-Arylmethyloxy-5-substitutent-n-arylbenzamide LRRK 2 Kinase Inhibitor

Selective Inhibitors of G2019S-LRRK2 Kinase Activity

Brain Penetrant LRRK2 Inhibitor.

Characterization of TAE684 As a Potent LRRK2 Kinase Inhibitor.

Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.

Discovery of potent LRRK2 inhibitors by ensemble virtual screening strategy and bioactivity evaluation

Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity.

Identification of Novel LRRK2 Inhibitors by Structure-Based Virtual Screening and Alchemical Free Energy Calculation.

Leucine-rich Repeat Kinase 2 Inhibitors: a Patent Review (2006 – 2011)

Clinical and Functional Evidence for the Pathogenicity of the LRRK2 P.arg1067gln Variant

Characterization of a Selective Inhibitor of the Parkinson’s Disease Kinase LRRK2

Identification of LRRK2 Inhibitors Through Computational Drug Repurposing.

LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation

Type-II kinase inhibitors that target Parkinson’s Disease-associated LRRK2

A Novel GTP-binding Inhibitor, FX2149, Attenuates LRRK2 Toxicity in Parkinson's Disease Models.

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Synthesis and Preliminary Evaluation of [C-11]GNE-1023 As a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson's Disease

Unveiling the Selectivity Mechanism of Type-I LRRK2 Inhibitors by Computational Methods: Insights from Binding Thermodynamics and Kinetics Simulation.

Novel LRRK2 GTP-binding Inhibitors Reduced Degeneration in Parkinson's Disease Cell and Mouse Models.

Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission

Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors